MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, VTYX had -$331K decrease in cash & cash equivalents over the period. -$17,558K in free cash flow.

Cash Flow Overview

Change in Cash
-$331K
Free Cash flow
-$17,558K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from maturities of mark...
    • Interest income
    • Stock-based compensation
    • Others
Negative Cash Flow Breakdown
    • Purchases of marketable securiti...
    • Accretion of marketable securiti...
    • Accrued expenses
    • Others

Cash Flow
2025-09-30
2025-06-30
Total operating expenses
84,304 -
Loss from operations
-84,304 -
Interest income
7,088 -
Other expense
-40 -
Total other (income) expense
7,048 -
Net loss
-22,829 -54,427
Depreciation
58 161
Amortization of right-of-use assets - operating
268 518
Stock-based compensation
4,601 9,606
Accretion of marketable securities, net
-1,063 -2,907
Prepaid expenses and other assets
-1,943 -1,988
Operating lease liabilities
-270 -500
Accounts payable
101 -2,236
Accrued expenses
-317 802
Net cash used in operating activities
-17,508 -46,995
Purchases of marketable securities, available-for-sale
34,774 53,348
Proceeds from maturities of marketable securities, available-for-sale
51,875 105,013
Purchases of property and equipment
50 58
Net cash provided by (used in) investing activities
17,051 51,607
Proceeds from exercise of stock options
203 -
Proceeds from issuance of common stock under employee stock purchase plan
0 68
Net cash provided by financing activities
203 68
Effect of exchange rates on cash, cash equivalents and restricted cash
-77 361
Net increase in cash, cash equivalents and restricted cash
-331 5,041
Cash and cash equivalents at beginning of period
28,235 -
Cash and cash equivalents at end of period
32,945 -
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from maturitiesof marketable...$51,875K Proceeds from exercise ofstock options$203K Net cash provided by(used in) investing...$17,051K Net cash provided byfinancing activities$203K Canceled cashflow$34,824K Net increase incash, cash...-$331K Canceled cashflow$17,254K Stock-based compensation$4,601K Prepaid expenses andother assets-$1,943K Amortization of right-of-useassets - operating$268K Accounts payable$101K Depreciation$58K Interest income$7,088K Purchases of marketablesecurities,...$34,774K Purchases of property andequipment$50K Net cash used inoperating activities-$17,508K Canceled cashflow$6,971K Effect of exchangerates on cash, cash...-$77K something is missing$54,427K Total other (income)expense$7,048K Canceled cashflow$40K Net loss-$22,829K Canceled cashflow$61,475K Accretion of marketablesecurities, net-$1,063K Accrued expenses-$317K Operating leaseliabilities-$270K Other expense-$40K Loss from operations-$84,304K Total operatingexpenses$84,304K

Ventyx Biosciences, Inc. (VTYX)

Ventyx Biosciences, Inc. (VTYX)